On August 11, 2025, Humacyte, Inc. announced its financial results for the second quarter ended June 30, 2025. The company reported total revenues of $301,000 for the quarter, contributing to $818,000 for the first six months of 2025, derived from sales and a collaborative research agreement.
Humacyte highlighted significant progress in the commercial launch of Symvess, with 82 civilian hospitals now having Value Analysis Committee (VAC) approval to purchase the product, a substantial increase from five hospitals in the previous quarter. Additionally, ECAT approval made Symvess available to approximately 190 Military Treatment Facilities and U.S. Department of Veterans Affairs hospitals.
The company noted an acceleration in VAC approvals in late June and July, with July product sales exceeding the total sales recorded during the first half of the year. Humacyte also achieved its first commercial sale to a U.S. military treatment facility in July, which has since re-ordered Symvess, demonstrating early market traction despite encountering some negative press.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.